Regulus Therapeutics Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenues
Revenue under collaborations
Total revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest and other income
Interest and other expense
Loss before income taxes
Income tax expense
Net loss
Net loss per share - basic and diluted (in dollars per share)
Weighted average shares used to compute basic and diluted net loss per share (in shares)
Other comprehensive loss:
Unrealized gain on short-term investments, net
Comprehensive loss
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted average shares used to compute basic net loss per share (in shares)
Weighted average shares used to compute diluted net loss per share (in shares)

Comments